Therapix Biosciences (NASDAQ:TRPX) received an initiation of coverage from Laidlaw & Company analyst Francois Brisebois who gave the company a Buy rating and a $18.00 price target. Therapix’s lead drug is an FDA approved dronabinol, which is a biosynthetic form of THC. The company’s strategy is to repurpose, reposition and improve the FDA approved cannabinoid for various....More>>>
8 Things Most Americans Dont Know About Retirement
Comments Flood In on DOL Fiduciary Rule Delay
Betterment Rebuffs Buffett, Says Sages Advice Doesnt Work Anymore
Developing the next generation of talent and worries over cybersecurity are the top priorities for RIAs, according to a just-released Investment Adviser Association and Cerulli Associates poll.
In the premier....More>>>
The management of regulatory affairs essentially contributes to the overall success of new drug development – both at early pre-marketing stages and at all times post-marketing. This means that a biotech or pharma company’s regulatory affairs personnel will be heavily involved in all stages of new drug development both prior to and after an FDA approval.
This is a guest contribution from The Financial Canadian
It is rare to find an investment that is both relatively safe and offers tremendous upside potential.
What if I told you that there was a smaller Canadian version of Warren Buffett’s Berkshire Hathaway (NYSE:BRK.B) that has both of these characteristics?
The company I’m talking about is Fairfax Financial Holdings....More>>>
I recently bought shares of seven different companies. One of those companies was AbbVie (NYSE:ABBV). I had different reasons for buying each of the stocks. Some were in sectors in which I didn’t already have much exposure in my portfolio. That wasn’t the case with AbbVie, though. I already owned quite a few healthcare stocks and exchange-traded funds (ETFs).
Pfizer (NYSE:PFE) has been gaining a lot of momentum recently with its share price having risen almost 7% since the 24th of January. The stock has been riding the biotech wave since the complex bottomed back in November but also has traded strongly since it announced its fourth quarter results at the end of January. Although the company missed earnings expectation in Q4 due to established....More>>>
Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in....More>>>
Regardless of which side of the political divide you fall on, you’ll probably agree that President Trump’s unorthodox leadership style is almost certainly going to create a fair amount of volatility in the market moving forward.
Keeping this theme in mind, I think the Dividend Aristocrats AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), and Medtronic plc (NYSE:MDT)....More>>>
With the election in the rear-view—and Inauguration Day just a few weeks off—plenty of investors have asked me what they should do with their portfolios now.
I’ll name five bargain dividend growers that should be on your buy list in a moment. But first, here are 2 sectors—and 9 stocks—you need to handle with care.
Let These 4 Growth Rockets Cool Down